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Iron is required in a variety of essential processes in the body. In this review, we focus
on iron transport in the brain and the role of the divalent metal transporter 1 (DMT1)
vital for iron uptake in most cells. DMT1 locates to cellular membranes and endosomal
membranes, where it is a key player in non-transferrin bound iron uptake and transferrin-
bound iron uptake, respectively. Four isoforms of DMT1 exist, and their respective
characteristics involve a complex cell-specific regulatory machinery all controlling iron
transport across these membranes. This complexity reflects the fine balance required
in iron homeostasis, as this metal is indispensable in many cell functions but highly
toxic when appearing in excess. DMT1 expression in the brain is prominent in neurons.
Of serious dispute is the expression of DMT1 in non-neuronal cells. Recent studies
imply that DMT1 does exist in endosomes of brain capillary endothelial cells denoting
the blood-brain barrier. This supports existing evidence that iron uptake at the BBB
occurs by means of transferrin-receptor mediated endocytosis followed by detachment
of iron from transferrin inside the acidic compartment of the endosome and DMT1-
mediated pumping iron into the cytosol. The subsequent iron transport across the
abluminal membrane into the brain likely occurs by ferroportin. The virtual absent
expression of transferrin receptors and DMT1 in glial cells, i.e., astrocytes, microglia and
oligodendrocytes, suggest that the steady state uptake of iron in glia is much lower than
in neurons and/or other mechanisms for iron uptake in these cell types prevail.
Keywords: iron, transferrin receptor, OX26, DMT1, blood brain barrier, Belgrade rat
Introduction
Iron is essential for virtually all eukaryotic cells and indispensable for cellular processes
such as DNA synthesis, mitosis, and metabolic processes that require synthesized
proteins such as enzymatic reactions and electron transport in the respiratory chain
Abbreviations: BBB, blood-brain barrier; DMT1, divalent metal transporter 1; Fe2+, ferrous iron; Fe3+, ferric iron;
IRE, iron response element; IRP, iron-responsive protein; NTBI, non-transferrin bound iron; TMD, transmembrane
domain.
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(Hentze et al., 2010; Anderson and Vulpe, 2009; Rouault, 2013).
Iron is involved in organ-specific functions e.g., in the brain,
where it is involved in synthesis of neurotransmitters and myelin
formation (Todorich et al., 2009; Rouault, 2013; Ward et al.,
2014). Disruption of the iron status dramatically affects cellular
functions, as both iron deficiency and excess compromise the
cell. Consequently, a tightly regulated system evolved to ensure
appropriate levels of available intracellular iron. Iron exists on
two different ionic forms in biological systems, i.e., ferrous
iron (Fe2+) and ferric iron (Fe3+; Anderson and Vulpe, 2009;
Hentze et al., 2010; Rouault, 2013). Outside cells, iron appears
on its oxidized, insoluble ferric form, and intracellularly, iron
mainly stays on its reduced, but soluble ferrous form. Oxidation
and incorporation by ferritin that also has ferroxidase activity
prevents ferrous iron from accumulating unbound, which
prevents iron from participating in unwanted oxidative reactions
prone to generate oxidative stress and subsequent cell damage.
The cellular iron-regulatory system is complex and involves
various proteins that collectively regulate import, neutralization,
storage and export of iron. Functions that are mainly denoted
by the transferrin receptor 1, divalent metal transporter 1
(DMT1), ferritin and ferroportin (Anderson and Vulpe, 2009;
Rouault, 2013). The intracellular iron level is monitored by
ubiquitously expressed iron-sulphur (Fe-S) cluster proteins,
iron-responsive protein 2 (IRP2) in particular. In case of
iron shortage, IRP2 loses its Fe-S cluster and binds to iron-
responsive elements of target mRNAs. This binding of IRP2
stimulates translation of mRNA encoding proteins involved
in cellular iron uptake (transferrin receptor 1 and DMT1)
and post-transcriptionally represses the expression of proteins
used for iron storage and export (ferritin and ferroportin)
(Anderson and Vulpe, 2009; Hentze et al., 2010; Rouault,
2013).
Orally administered non-heme iron mainly enters the
circulation via absorption by duodenal enterocytes in the gut.
Ferric iron is reduced to ferrous iron by ferric reductase present
on the apical surface of the enterocytes and subsequently
transported across the apical cell membrane by DMT1
(Anderson and Vulpe, 2009; Hentze et al., 2010; Rouault, 2013).
Conversely, heme-bound iron enters enterocytes by amechanism
not involving DMT1 but mediated by heme transporter carrier
protein 1 (HCP1; Shayeghi et al., 2005). The iron-containing
heme-complexes are degraded by heme-oxygenases, and the
release of ferrous iron inside the enterocyte is subsequently
exported into blood plasma by the iron-transporter, ferroportin
(Anderson and Vulpe, 2009; Hentze et al., 2010; Rouault,
2013). Ferroportin operates in conjunction with the ferroxidases
hephaestin and ceruloplasmin, which oxidize ferrous iron to
ferric iron during the export from the enterocyte (Vulpe et al.,
1999).
Once present in blood plasma, ferric iron is rapidly
bound to apo-transferrin to form holo-transferrin, which
binds two iron atoms. The iron uptake from holo-transferrin
rely on the expression of transferrin receptor 1 present on
the plasma membrane in many cell types, which ensures
receptor-mediated endocytosis (Harding et al., 1983). The
expression of transferrin receptor 1 is notably high on
hepatocytes and neurons, the rapidly dividing cells of the
erythron, and stem cells of the gut and skin (Rouault, 2013;
Ward et al., 2014). Interestingly, endothelial cells of the
vasculature with immediate access to holo-transferrin of the
blood plasma do not contain detectable transferrin receptors,
except for brain capillary endothelial cells that form the blood-
brain barrier (BBB; Jefferies et al., 1984). The binding of
holo-transferrin to the transferrin receptor quickly mediates
uptake of the complex via clathrin-coated pits. The pH-
value of the holo-transferrin/transferrin receptor complex-
containing endosome drops to approximately 5.5 during the
internalization process due to acidification promoted by an
H+-ATPase proton pump in its membrane. The resulting acidic
environment inside the endosome triggers the release of iron
from transferrin (Dautry-Varsat et al., 1983). Furthermore,
the ferrireductases like Steap3 reduces ferric iron to ferrous
iron, and DMT1 pumps iron out of the endosome into the
cytosol (Knutson, 2007). Transferrin receptor 1 recycles to the
cell surface from where apo-transferrin is released into blood
plasma ready for another iron-capture and intracellular iron-
releasing cycle (Ciechanover et al., 1983; Dautry-Varsat et al.,
1983).
The robust affinity of transferrin for iron is responsible for
the complete absence of non-transferrin bound iron (NTBI)
in normal conditions. However, in conditions with excess iron
uptake from the gut or parenteral iron infusion, the iron-binding
capacity of transferrin can be exceeded leaving to pathological
deposition of iron widely in the body, a clinical condition called
hemochromatosis (Ayonrinde et al., 2008; Brissot et al., 2011).
Transferrin receptor 2, located on hepatocytes, senses
the saturation of extracellular, circulating transferrin, and a
complex consisting of transferrin receptor 1, β2-microglobulin
and hereditary hemochromatosis gene product located on
membranes of dividing cells senses any excess intracellular
iron and signals for an up-regulated synthesis and secretion
of hepcidin (Chua et al., 2007; Worthen and Enns, 2014).
The peptide hormone hepcidin is secreted from the liver and
regulates body iron stores (Nemeth et al., 2004). Hepcidin
has high affinity for ferroportin and post-translationally
down-regulates ferroportin expression, thus hepcidin binding
to ferroportin leads to its subsequent degradation, hereby
lowering iron transport into the circulation (Nemeth et al.,
2004).
Outline
In this review, we evaluate the literature on uptake and
transport of iron in the brain with a focus on delineating
the possible roles of DMT1. The available literature reports
on mutations in man, studies on normal and mutated rodent
models, and various cellular models manipulating DMT1. We
critically evaluate this literature and correlate the functions
of DMT1 for iron uptake and transport in the brain with
those published in non-neuronal tissues. As DMT1 is thought
to play its significant function in concerted action with
the transferrin receptor, we place special emphasis on the
uptake and transport of iron in brain capillary endothelial
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cells and neurons, i.e., the two principal cell types with the
highest expression of transferrin receptors in the brain (Moos
et al., 1998, 2007). That neurons contain DMT1 is widely
accepted, but the expression of DMT1 in brain capillary
endothelial cells is a site of conflict, suggesting that iron
could access the brain without involvement of DMT1. We
include new data in this review that do signify a soft-spoken
but significant expression of DMT1 for iron transport into
the brain. The review also covers the role of DMT1 for
iron uptake in neurons and non-neuronal cells of the brain,
i.e., astrocytes, microglia and oligodendrocytes in health and
pathology.
DMT1 Protein Structure and Function
The DMT1 protein, also known as Nramp2, SLC11A2, and
DCT1, conducts iron transport at two distinct compartments of
the cell: (1) It facilitates iron uptake at the apical cell membrane
in for instance duodenal enterocytes (Anderson and Vulpe, 2009;
Hentze et al., 2010; Rouault, 2013); and (2) It transports iron
across the endosomal membrane in almost all cell types that take
up iron via the transferrin-transferrin receptor 1 pathway, e.g.,
erythroid precursors in the bone marrow (Canonne-Hergaux
et al., 2001), and most cells in peripheral tissue. DMT1 functions
optimally at an acidic pH of approximately 5.5, which fits well
with the pH values in both the duodenum and inside the
endosome.
DMT1 is a member of the natural resistance associated
macrophage protein (Nramp) family. This highly conserved
protein family consists of a varied group of membrane-bound
divalent cation transporters (Cellier et al., 1995). Functional
homologues of the Nramp proteins are found in bacteria (Makui
et al., 2000; Agranoff et al., 2005). DMT1 transports divalent
cations in exchange for one single proton (Gunshin et al.,
1997). The substrate profile of DMT1 includes other metals
than iron. For instance membrane-located 1A/(+IRE) DMT1
transports Fe2+, Cd2+, Co2+, Mn2+ (group 1), and Ni2+, VO2+,
Pb2+ (group 2), but with decreasing efficiency, and group 1
being markedly more effectively transported than group 2. Zn2+
is not transported by DMT1 (Mackenzie et al., 2007). Other
cations, such as Cu1+ and Cu2+ are also transported by DMT1
(Arredondo et al., 2003).
The DMT1 protein has 12 transmembrane domains,
membrane targeting motifs, one consensus transport motif,
and two asparagine-linked glycosylation signals in an extra
cytoplasmic loop (Figure 1). Both the N- and C-terminus of
the protein are located in the cytoplasm. Several studies have
elucidated the structure-function relationship of Nramp H+-
coupled divalent metal transport: The transmembrane domain 1
(TMD1) and TMD6 are crucial for Nramp symport of metal ions
and H+ ions (Chaloupka et al., 2005).
DMT1 was first identified in the mouse in 1995 (Gruenheid
et al., 1995) and later cloned from a cDNA library prepared
from duodenal mRNA in rats fed a low iron diet (Gunshin
et al., 1997). The DMT1 gene comprises 17 exons and spans
more than 36 kb. There are two alternative transcripts of the
3′ UTR, which were later identified as one with an iron response
element (+IRE; Type 1) and one without an IRE (−IRE; Type
2; Tchernitchko et al., 2002). The IRE is a conserved stem loop
structure, which by binding specific iron-response proteins in
the cell mediates modified stability or translation efficiency of the
givenmRNA. Two additional transcripts have DMT1 differing in
the 5′ region: One mRNA transcript starts in exon 1A, skips the
next exon (1B), and splices directly with exon 2. Another mRNA
transcript, the first identified, skips exon 1A, starts in exon 1B
and splices with exon 2 (Hubert and Hentze, 2002). Exon 1A has
an initiation codon (AUG), and variant 1A has a 29–31 amino
acid extension in contrast to variant 1B, where the initiation
codon is located in exon 2. The four identified DMT1 isoforms,
1A/(+IRE), 1A/(−IRE), 1B/(+IRE), and 1B/(−IRE) share 543
amino acid residues (Figure 1). The 3′ end of the IRE variant is
unique for each variant and consists of 25 (−IRE) and 18 (+IRE)
amino acids, respectively. A miRNA target sequence for let-7d
is present in the 3′UTR of the (–IRE) DMT1 isoforms. Let-7d
binds and participates in regulating the (–IRE) DMT1 isoform
in erythroid cells (Andolfo et al., 2010). Differences occur in
translational efficiency between the four isoforms (Mackenzie
et al., 2007), and protein degradation pathways vary between the
IRE isoforms. 1B isoforms are degraded by the ubiquitin E3-
ligase parkin, whereas the 1A isoforms are not (Garrick et al.,
2012).
The four DMT1 isoforms exhibit different organ-specific
expression patterns. The 1A transcripts occur almost exclusively
in polarized cells in duodenum and kidney, whereas the
expression of 1B transcripts is ubiquitous. The expression of
both of the IRE variants is to some extent found in most tissues.
Therefore, the organ specific expression of DMT1 seems to
depend on elements in the promoter of the 1A variant or in
the 1A region itself (Hubert and Hentze, 2002). The subcellular
distribution of the four isoforms varies as shown by anti-DMT1
immunocytochemistry on Xenopus oocytes transfected with each
of the four DMT1 variants, respectively. The (+IRE) variants
are localized to the cell membrane, whereas the (−IRE) variants
are not (Mackenzie et al., 2007). The fact that there are four
different isoforms of DMT1 might also reflect various functional
properties. Importantly, however, the four isoforms transport
Fe2+ at the same turnover rate and exhibit no differences in
their functional properties, permeant ions or rate limiting steps
(Mackenzie et al., 2007). Other studies have also failed to detect
functional differences of the various isoforms (Garrick et al.,
2006). Hence, the existence of the four isoforms is suggested
to meet the need of cell type specific subcellular targeting and
regulation (Mackenzie et al., 2007).
Iron Regulates DMT1 Expression both
Transcriptionally and
Post-Transcriptionally in Non-Neuronal
Cells
Papers published before 2002 report on both DMT1 IRE
isoforms, but do not take the structure of the 5′ end of the DMT1
mRNA into consideration. This may affect the interpretation
of data, as results may reflect effects of either of the 1A and
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FIGURE 1 | Schematic representation of mouse Nramp2 (DMT1)
isoform II (−IRE) and isoform I (+IRE) modified from
Lam-Yuk-Tseung et al. (2003) by adding the IA and IB isoforms.
The 12 transmembrane domains and 13 Individual predicted intracellular
and extracellular segments are identified, and their position within the
primary sequence is shown. Amino acid residues defining sequence
landmarks and signature motifs are depicted in different colors, including
negatively and positively charged residues within predicted TM domains
(dark blue), conserved histidine residues in TM6 (red), glycine residues in
TM4 altered in anemic mk/Belgrade mutants (Gly185Arg), and mutated (in
Nramp1) in mice susceptible to infections (Gly184Asp) (yellow). Also
identified are Asn-linked glycosylation signals in the TM7-TM8
extracytoplasmic loop (black), predicted membrane targeting/sorting
motifs (tyrosine-based and dileucine) (green), and consensus transport
signature common to Nramp orthologs and present in the cytoplasmic
face of membrane anchors of bacterial periplasmic permeases (orange).
The two different C-termini of the protein generated by alternative mRNA
splicing containing or not an iron response element (isoform I, +IRE;
isoform II, IRE) in the 3′ untranslated region are identified, with
corresponding numbering. Adapted from Lam-Yuk-Tseung et al. (2003).
1B isoforms. A thorough study from 2002 elucidated the gene
expression and transcriptional regulation of all four isoforms
of DMT1 with respect to changes in iron levels (Hubert and
Hentze, 2002). The study included semi-quantitative PCR on
Caco-2 cells, and onmouse duodenum and kidney, using primers
specific for each of the four isoforms. The results showed
that the 1A region is the main player with respect to iron-
dependent regulation of DMT1 expression in Caco-2 cells and
duodenum. The 3′UTR with the IRE element also contributed
to iron-responsive regulation, but to a lesser extent (Hubert
and Hentze, 2002). Furthermore, the DMT1 IRE element has
no effect on DMT1 expression in the colon cell line HT-
29 transfected with a plasmid encoding a reporter with the
(+IRE) 3′UTR of DMT1 (Tchernitchko et al., 2002). These
results describe DMT1 mRNA data but additional levels of
regulation may affect the protein, e.g., protein relocation in
response to excess iron occurs in intestinal Caco-2 cells, which
normally express high levels of cell membrane-bound DMT1.
In Caco-2 cells subjected to high levels of non-heme iron, the
level of cell membrane-bound DMT1 decreases without parallel
changes in total mRNA levels, including both IRE isoforms.
This relocation may be a rapid response regulatory mechanism
for immediate response to changes in iron levels (Sharp et al.,
2002).
Mutations in the DMT 1 Gene Affect
Gastrointestinal Iron Absorption, and
Tissue Iron Deposition
DMT1 is significantly implicated in gastrointestinal absorption
of iron as demonstrated in two animal models: the microcytic
anemia (mk) mouse and in the Belgrade rat. Both of these
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rodents have a spontaneous G185R missense mutation in DMT1
located in the conserved TMD4 region (Figure 1) irrespective of
isoform that causes defective DMT1 protein expression without
complete loss of function (Gunshin et al., 2005). The DMT1
protein carrying the G185R mutation is abnormally glycosylated,
less stable, and 20–35-fold less active in metal transport (Fleming
et al., 1998; Su et al., 1998; Canonne-Hergaux et al., 2001). The
Belgrade rat displays a phenotype with anemia. It has liver iron
loading, possibly due to due impaired erythropoiesis (Thompson
et al., 2006). It also has a lower concentration of iron in the brain
(Farcich and Morgan, 1992; Burdo et al., 1999). Themkmouse is
poorly viable although able to survive for more than a year (Xu
et al., 2004).
Dietary iron-supplementation leads to increased hematocrit
in the Belgrade rat (b/b; Thompson et al., 2006). Although
the increase is lower than in age-matched heterozygotes (b/+),
Belgrade rats absorb some intestinal iron despite defects in
DMT1 function. A murine DMT1 knockout model shows a
more severe phenotype than seen in the animals with the
G185R missense mutation (Gunshin et al., 2005). Pups only
survive for 1 week after birth, probably due to severe anemia,
as the iron stores rapidly deplete, which confirms that DMT1
is the major intestinal iron transporter for non-heme iron from
the diet in these murine models. The G185R mutation, reported
independently at least three times in rodents, is remarkable. This
coincidence suggests a gain of function of the DMT1 protein
carrying the G185R mutation (Xu et al., 2004).
Rare cases of DMT1 mutations in humans occur, although
it is a rare and under-diagnosed condition with an estimated
prevalence of less than 1:1.000.000 (Mims et al., 2005; Beaumont
et al., 2006; Iolascon et al., 2006; Blanco et al., 2009; Bardou-
Jacquet et al., 2011)1. In contrast to rodents in where heme iron
is poorly absorbed, one third of dietary iron in humans derives
from heme iron and therefore bypasses the DMT1 route of
the duodenal uptake (Conrad and Umbreit, 2000). Accordingly,
mutations in DMT1 in man will primarily affect cellular iron
uptake and utilization more than iron absorption, which leads to
a somewhat different phenotype than the one seen in the rodents.
The literature reports on five mutations in the human DMT1
gene, i.e., a 1285G>C mutation: The patient is homozygous for
the mutation, which results in both a conservative amino acid
substitution (E399D) and a preferential, but incomplete, skipping
of exon 12 during RNA processing (Lam-Yuk-Tseung et al., 2005;
Mims et al., 2005). A missense mutation (1246C>T, R416C)
located in a conserved sequence in TMD9 and an additional 3bp
deletion in intron 4 (c.310-3_5del) leading to aberrant mRNA
splicing of exon 5 (Iolascon et al., 2006; Lam-Yuk-Tseung et al.,
2006). A 3 bp exonic deletion in exon 5 removing residue V114,
and a missense mutation in exon 8 leading to the exchange of a
conserved amino acid (G212V), which in turn leads to changes
in TMD2 and TMD5, respectively (Beaumont et al., 2006). A
fourth patient has a N491S mutation and a G212Vmutation. The
N419S mutation results in disturbed protein trafficking, and the
protein ends up in the endoplasmic reticulum (Bardou-Jacquet
et al., 2011). The clinical phenotypes of these patients are, like
1www.enerca.org
in the Belgrade rat, microcytic anemia and liver iron overload,
but none reports on pathological levels of iron in the brain. A
fifth patient who is homozygous for the mutation G75R located
in TMD1, displays a partly different phenotype, as no liver iron
overload is observed (Blanco et al., 2009). This patient was only
7 years old at the time of publication, and the authors state that a
possible later development of iron overload is possible.
The iron transfer between the mother and the fetus occurs
via transferrin receptors expressed at the apical membrane
of the placental cells (Cetin et al., 2012). However, the
normal transferrin-transferrin receptor 1 route is apparently
not exclusive, as demonstrated by studies in DMT1 knockout
mice in where neonatal hematological parameters are normal
(Gunshin et al., 2005). Moreover, the liver also seems to have
an alternative route for iron uptake in the fetus, as liver iron
stores are large and even elevated immediately after birth in the
DMT1 knockout mice as compared to wild type mice (Gunshin
et al., 2005). The iron overload in the liver in animal models
and patients with DMT1 mutations may therefore be due to iron
uptake through a DMT1-independent route and a subsequent
disruption of the DMT1-mediated iron delivery essential to
hemoglobin production for erythropoiesis (Thompson et al.,
2006).
The Expression of DMT1 in Brain
The gene expression of the DMT1 in the brain presumably solely
relies on the 1B isoform of the N-terminal that is expressed
together with both IRE isoforms (+/− IRE) in the mouse brain
(Hubert and Hentze, 2002). Recent studies confirm that the
brain expresses the two IRE isoforms of the C-terminal (Ke
et al., 2005), and that the 1A is not expressed in neurons
of the rat brain (Pelizzoni et al., 2012). At the protein level,
the consensus is less clear. The DMT1 is present in the brain
when examined using two different antibodies that detect the
conserved regions (Moos et al., 2000; Burdo et al., 2001). DMT1
is also detectable using an antibody that detects the IRE isoforms
(Moos and Morgan, 2004). The detection of immunoreactivity
of the 1A form using a polyclonal antibody is more questionable
given the data from the gene expression analyses (Hubert and
Hentze, 2002) and may rely on cross-reactivity between the
DMT1 isoforms. The scarce expression of the IRE isoforms
in the developing brain follows with an increase during the
first postnatal weeks (Moos and Morgan, 2004; Ke et al.,
2005; Moos et al., 2006). The cellular distribution of DMT1-
immunoreactive cells in the brain remains controversial. Clearly,
consensus points towards a sustained expression in neurons,
whereas studies report on varying protein expression in DMT1 in
non-neuronal cells: Astrocytes, microglia and oligodendrocytes,
and the two principal cell types that form the brain barriers to
molecules of the blood, i.e., brain capillary endothelial cells and
choroid plexus epithelial cells. The virtual absent expression of
transferrin receptors and DMT1 in vivo in astrocytes, microglia
and oligodendrocytes suggests that the steady state uptake of
iron in glia in physiological conditions is much lower than in
neurons and/or other mechanisms for iron uptake in these cell
types prevail (see below).
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DMT1 has a Role for Iron Transport into
the Brain
The transport of iron across the endothelial cell layer of the
BBB is still not fully explained. The main inducer of iron
uptake is the binding of circulating holo-transferrin to transferrin
receptor 1 expressed on the luminal side of the brain capillary
endothelial cells (c.f. Rouault and Cooperman, 2006; Moos et al.,
2007). This capillary expression is specific for the brain and
spinal cord and exerts a pattern where approximately 10% of
the transferrin receptors can be detected on the cell surface,
whereas the remaining 90% are presumably located as a spare
pool inside the cytoplasm (van Gelder et al., 1995; Visser et al.,
2004). Brain iron deficiency is accompanied by an increase in
iron uptake across the BBB, but interestingly this is not due to
an increased expression of brain endothelial transferrin receptors
(Figure 2) (Moos et al., 1998). Instead, the increased iron uptake
under these conditions is due to a raise in the cycling rate
of transferrin receptors (Moos and Morgan, 2001; Moos et al.,
2007).
Subsequent to the transferrin receptor-mediated binding and
resulting uptake of holo-transferrin at the BBB, the iron bound
to transferrin has to traverse the cell to undergo release on
the abluminal side into the brain interstitium. The mechanism
for this movement, however, is highly debated, but two main
hypotheses stand out: (1) Receptor-mediated transcytosis leading
to release of holo-transferrin inside the brain interstitium; and
(2) Receptor-mediated endocytosis of transferrin followed by
reduction of iron inside endosomes and retro-endocytosis of
apo-transferrin to the luminal surface. Fe2+ is pumped out of
the endosome into the cytosol by DMT1 and transported to
the abluminal side, where facilitated transfer occurs across the
abluminal membrane by ferroportin followed by re-oxidation to
Fe3+ due to the ferroxidase activity of ceruloplasmin (Moos et al.,
2007).
Concerning the first hypothesis (Hypothesis I), there is no
evident quantitative transport of transferrin through the BBB
(Crowe and Morgan, 1992; Strahan et al., 1992; Moos et al.,
2006), which we have covered in previous reviews on brain
capillary endothelial cells (Moos and Morgan, 2000; Moos
et al., 2007). The bulk of iron taken up by brain capillary
endothelial cells undoubtedly undergoes transport further into
the brain, but there is no evidence of a similar transport
of transferrin. Noteworthy, transferrin remains un-degraded
within brain endothelial cells, which could otherwise be a
plausible explanation for the much higher uptake of iron than
of transferrin (Strahan et al., 1992). Intravenously injected [59Fe-
125I] transferrin leads to formation of non-transferrin-bound
59Fe in the brain, which also favors hypothesis I on iron
being detached from transferrin within the brain endothelial
cells (Moos et al., 2007). Newer studies of antibody-mediated
drug delivery to the brain via the transferrin receptor suggest
that modification of the antibody affinity towards mimicking
that of endogenous transferrin may induce transcytosis (Yu
et al., 2011; Niewoehner et al., 2014; Pardridge, 2015). This
could rely on a mechanism where the lower affinity for the
transferrin receptor leads to detachment from the receptor
FIGURE 2 | Transferrin receptors in the normal and iron-deficient
developing and adult brain. (A) Binding of a monoclonal antibody to the
transferrin receptor (OX26) in the developing rat brain. The binding is
expressed as % ID/g weight ± SD. The uptake of OX26 is age-dependent
being highest in P15 brains. Iron-deficiency does not affect the uptake of
OX26 in injected P15 rats. , adult rat; , P15 normal rat; ◦, P15
iron-deficient rat; • P0 rat (Moos and Morgan, 2001). (B–E) Transferrin
receptor immunoreactivity (TR-ir) in the pyramidal cell layer (layer V) of the
neocortex from P21 (B,C), and adult rat brain (D,E). In the young (P21) rat
brain (B), brain capillaries and neurons (arrow) display TR-ir. When subjected
to iron deficiency neuronal TR-ir is elevated in the P21 brain (C). In the normal
adult rat brain (D), TR-ir is seen in pyramidal neurons. The TR-ir in brain
capillaries is much less pronounced than at P21. Following iron deficiency, a
higher TR-ir is seen in pyramidal neurons of the iron deficient rat (E) without
changes in the capillary TR-ir. Scale bars 20 µm. Below. Summary of
transferrin receptor immunoreactivity (TR-ir) and transferrin binding in brain
capillary endothelial cells (BCEC) and neurons (N) of control and iron deficient
rats at different stages of development. The levels of TR-ir and transferrin
binding were evaluated in four degrees: +++, very strong, ++, strong, + weak,
−, absent. nd, Not determined. Levels of transferrin binding was determined
by in vivo uptake (Taylor and Morgan, 1990; Taylor et al., 1991; Crowe and
Morgan, 1992) and in vitro receptor autoradiography (Moos et al., 1998).
Adapted from Moos et al. (1998) and Moos and Morgan (2001).
inside transcytotic vesicles, followed by release into the brain
interstitium by non-specific exocytosis. Counteracting this
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observation, injection of holo-transferrin with high affinity
for the rat transferrin receptor in young rats with high
transferrin receptor expression at the BBB is not accompanied
by transcytosis (Moos et al., 2006).
Regarding the second hypothesis (Hypothesis II) in an effort
to explain the apparent absences of DMT1 and ferroportin,
it was hypothesized that iron would be transported through
the brain endothelial cells without the involvement of an
endosomal escape mediated by DMT1 with little or no iron
being pumped out of the trafficking vesicles into the cytosol
(Moos et al., 2007). Moreover, according to this proposed
theory, the vesicle could dock at the abluminal surface of the
brain capillary endothelial cells where, facilitated by extracellular
factors present in the local abluminal microenvironment, iron
could detach from transferrin mediated by a decrease in the
extracellular pH and be released in the brain interstitium. Such
factors could derive from astrocytic release and might include
ATP, hydrogen ions, nucleotides and citrate (Morgan, 1977,
1979). Favoring the influence of astrocytes, they form end-
feet with intimate contact with the brain capillaries and cover
approximately 95% of their basal lamina (Brightman and Reese,
1969; Kacem et al., 1998; Abbott et al., 2006). Moreover, the
distribution and transport of iron within brain endothelial cells
is dramatically different in the developing rat brain at the time
point where astrocytes have not yet formed contact with the
brain capillaries (Moos et al., 2006). Declining the appraisal of
hypothesis II, examination of the in vivo expression of DMT1
revealed an abundant expression in neurons but not at detectable
levels in brain endothelial cells in spite using high sensitivity
immunoassays (Figure 3) targeting different epitopes on DMT1
(Moos et al., 2006). Gene expression analysis failed to confer
DMT1 among transporters in isolated rat brain endothelial cells
capillaries (Enerson and Drewes, 2006), which confer earlier
observations failing to DMT1 mRNA in endothelial cells of
the mouse brain (Gunshin et al., 1997). On the contrary, we
have recently demonstrated a quite low expression of both
DMT1 and ferroportin mRNA and protein in primary culture
of rat brain endothelial cells with confined BBB properties
(Figure 4; Burkhart, 2015). Therefore, these results indicate
that the expression of DMT1 in brain endothelial cells is low.
Supporting the latter, studies in the homozygous Belgrade b/b
rats revealed that uptake of iron in isolated brain capillaries
was lower, but also that the major quantitative difference in
iron uptake between heterozygous Belgrade b/+ occurred in
the postvascular compartment containing the neurons that are
strong in DMT1 expression (Moos et al., 2006). Furthermore,
short-term perfusion studies (5 min) performed in young
Belgrade rats showed that the percentage of iron present in
the brain capillary fraction was lower, albeit only slightly, in
the Belgrade rat than in controls (Moos et al., 2006). We
believe our recent identification of DMT1 and ferroportin in
carefully purified brain capillaries strongly favor the notion
of detachment of iron from transferrin inside endosomes
followed by efflux into the brain interstitium (Figure 5). In
support of this notion, recent studies also detected ferroportin
and ferroxidases in cultured brain endothelial cells (McCarthy
and Kosman, 2013; McCarthy et al., 2014). Probably, the
presumably low expression of DMT1 in the brain endothelial
cells is sufficient to balance the iron entering endosomes
subsequent to receptor-mediated internalization of transferrin,
hence supporting hypothesis II.
A recent study suggests that brain endothelial cells should be
regarded as more than a simple conduit where iron is merely
transported through, but as a reservoir of great importance
in the regulation of brain iron homeostasis via signaling from
the brain interior to regulate the trafficking of the transferrin
receptors cycling (Simpson et al., 2015). The iron status within
the brain interstitium may well be reflected in the percentage
of transferrin saturation with iron and probably also the
presence of non-transferrin bound iron. As a prerequisite for
the very original consideration on regulated iron transport from
the brain endothelium and further into the brain proposed
by Simpson et al. (2015). The brain endothelium needs to
express transferrin receptors at its abluminal side to sense
the transferrin saturation within the brain, but so far the
detection of transferrin receptors there is limited and without
consensus. However, the presence of non-transferrin bound
iron may enter the brain endothelial cells from the brain
interior and thereby affect the recycling of the transferrin
receptor.
Uptake of Non-Transferrin Bound Iron at
the Blood-Brain Barrier
Whether circulatory iron excess leads to iron deposition in the
brain in hemochromatosis is site of dispute. Recent studies imply
that hereditary hemochromatosis can affect the handling and
acquisition of iron with neurons and glia (Bartzokis et al., 2011;
Acikyol et al., 2013). Concerning blood to brain transport of
iron, rodents with experimentally induced hemochromatosis do
not accumulate iron in the brain (Moos et al., 2000). There
is no evidence for uptake and transport of non-transferrin
bound iron at the BBB even under conditions with experimental
hemochromatosis where the iron-binding capacity of transferrin
is exceeded (Kim et al., 2013). Theoretically, expression of
the 1A isoform of DMT1 in the luminal membrane of brain
capillary endothelial cells could allow circulatory non-transferrin
bound iron to enter brain. However, as previously stated there
is no solid evidence for expression of the 1A isoform in
these cells.
The Participation of DMT1 in Neuronal Iron
Uptake
In contrast to brain capillaries, neurons upregulate their
expression of the transferrin receptor and transferrin binding
in iron deficiency (Moos et al., 1998). Neurons do not increase
their expression of the DMT1 IRE isoforms in iron depleted
conditions (Ke et al., 2005). The neuronal DMT1 seems to
co-localize with transferrin-receptor containing endosomes and
probably participates in the uptake of iron subsequent to the
binding and internalization of holo-transferrin to the neuronal
transferrin receptor (Moos et al., 2007; Rouault, 2013; Ward
et al., 2014). Hence, there is good reason to believe that neurons
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FIGURE 3 | Expression of DMT1 in Wistar (A,C,D,G,H,I) and b/b (B,E,F)
rat brains. (A,B) Sections from the mesencephalon containing the red
nucleus (RN) and the interpedunculate nucleus (IP) shown at low power
magnification. The DMT1 expression is not higher in the b/b brain. (C,E)
Sections showing the RN at medium power. DMT1 immunoreactivity is seen
in neurons of both rat strains. The intensity of the neuronal DMT1
immunoreactivity does not differ between the two rat strains. (D,F) Labeled
neurons from the RN shown at high power. Note the punctuated
immunoreaction product that distinctly labels the perikarya and leaves the
nucleus unstained. (G) Section from the pyramis of the brainstem. Whereas
brainstem neurons of the reticular formation (top) are consistently labeled,
elements of the neighboring white matter (wm) are virtually unstained.
(H) High contrast image taken from the lower brainstem shown at high
power. Elements with morphology corresponding to transected brain
capillaries are unlabeled (the asterisk identifies a transected capillary). A
labeled neuron is also seen. (I) DMT1 in choroid plexus epithelial cells of the
third ventricle. Scale bars: A,B = 175 µm; C,E = 20 µm, D,F,H,I = 10 µm,
G = 30 µm. Illustrations partly adapted from Moos and Morgan (2004).
acquire iron by the well-described, mechanism occurring in
cells outside the brain where transferrin receptor-mediated
internalization leads to iron transport to the endosome and
retro-endocytosis of apo-transferrin and transferrin receptor-
containing coated pits to the neuronal surface. Iron is then
subsequently reduced by ferrireductases inside endosomes,
pumped into the cytosol by DMT1 to participate in the neurons’
metabolism if not stored in ferritin or transported out of the cell
by ferroportin (Moos et al., 2007; Rouault, 2013; Ward et al.,
2014).
Neurons take up non-transferrin bound iron in vitro
(Pelizzoni et al., 2012; Ji and Kosman, 2015), and the presence
non-transferrin bound iron in the intact brain (Moos and
Morgan, 1998) suggests that this uptake probably also occurs
in vivo. Concerning a role for DMT1 for non-transferrin
bound uptake in vivo the evidence is unclear. Probably, such
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FIGURE 4 | Gene expression analyses for molecules related to iron
uptake in vivo and in BBB cultures. (Left) Divalent metal transporter I
(DMT1). (Right) Ferroportin. Gene expression was analyzed in purified
brain capillaries from 21 days old rats, which were subsequently cultured
in primary co-culture with astrocytes to enable a confined BBB in vitro
rat brain endothelial cells (RBEC). The expression was compared with an
immortalized cell line, RBE4. The expression of both DMT1 and
ferroportin is present in both purified capillaries and primary cultures.
Data are normalized to β-actin and presented as means ± SEM (n = 6).
**p < 0.01, ***p < 0.001 (Burkhart, 2015).
FIGURE 5 | Drawing showing a model proposing the transport of
iron through the blood-brain barrier without (left) or with (right)
transcytosis of transferrin. (Left) The recent identifications of Steap,
DMT1 and ferroportin in carefully purified brain capillaries strongly favor
that iron gets detached from transferrin inside endosomes, which is then
followed by iron efflux into the brain interstitium mediated by ferroportin.
This is the model that is referred to Hypothesis I in the text. (Right)
drawing showing the claimed transcytosis of holo-transferin through the
brain capillary endothelial cell, which in the text is referred to as
Hypothesis II.
uptake would require the expression of the 1A isoform in
the cellular membrane of neurons but this is not the case
(Pelizzoni et al., 2012). Interestingly, however, transfection of
the 1A form into primary hippocampal neurons provides the
requisite for uptake of non-transferrin bound iron (Pelizzoni
et al., 2012).
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The role of DMT1 for neuronal iron handling in pathological
studies is vaguely studied, but some interesting data have
occurred. Mice mutated in DMT1 better overcome the toxic
insult than control littermates in an experimental model
for Parkinson’s disease, probably because the tendency
towards iron accumulation is reduced (Salazar et al., 2008).
Mutated Parkin is a cause of early onset of Parkinson’s
disease, and Parkinson’s disease patients with mutated
Parkin have higher levels of 1B/(+IRE) DMT1, reflecting
the impairment of the ubiquitin E3-ligase activity (Roth
et al., 2010). Reduction of another ubiquitin ligase Nedd4
family-interacting protein 1 (Ndfip1) could contribute to
neurodegeneration via dysregulation of its regulation of
DMT1 degradation (Howitt et al., 2014; Jia et al., 2015).
Possibly this could lead to increased neuronal iron uptake
and propagate iron-mediated oxidative stress and damage.
The expression of both 1B/(−IRE) DMT1 and intracellular
iron influx are increased in brain ischemia (Ingrassia et al.,
2012). DMT1 +IRE is downregulated in 6-hydroxydopamine
intoxicated, cultured dopaminergic neurons treated with brain-
derived neurotrophic factor (BDNF) and glial cell line-derived
neurotrophic factor (GDNF) (Zhang et al., 2014), but elevated
following treatment with angiotensin (Garrido-Gil et al.,
2013).
DMT1 is Virtually Absent from Glial Cells In Vivo
but Contributes to Iron Uptake in Astrocytes
In Vitro
There is solid evidence for DMT1 expression in astrocytes in
vitro but the in vivo evidence is more scarce (Burdo et al.,
2001; Lis et al., 2004; Moos and Morgan, 2004; Huang et al.,
2006; Pelizzoni et al., 2012). Interestingly, astrocytes do not
express detectable levels of transferrin receptors in vivo but
clearly in vitro and in primary rat astrocytes (Qian et al.,
1999; Lis et al., 2004; Pelizzoni et al., 2012). The amount of
available iron relative to the iron need regulates the expression
of both transferrin receptor 1 and DMT1, and the differences
between in vivo and in vitro conditions could possibly be
attributed to the much higher proliferating state of cultured cells
in vitro.
Western blot analyses of DMT1 purified from neurons and
astrocytes show that the molecular mass of DMT1 in the two
cell types differs (Pelizzoni et al., 2012). The DMT1 from
neurons produces a band corresponding to the expected ∼64
kDa, whereas astrocytes produce one of slower mobility. The
size of the band obtained from astrocytes corresponds to those
obtained from duodenal enterocytes. In astrocytes treated with
an N-glycosylation-inhibitor, the DMT1 bands from neurons
and astrocytes are both ∼50 kDa, suggesting that DMT1 is
differentially glycosylated in the two types of brain cells. As the
same pattern of glycosylation exists for DMT1 in enterocytes
known to acquiesce NTBI, a subcellular localisation with an
extracellular presentation of DMT1 could confer transferrin-
independent iron uptake across the cell membrane.
Cultured astrocytes seem to harbor distinct routes through
which NTBI enters the cells. One route mediates the uptake of
ferrous iron and depends on DMT1 and ascorbate (Lane et al.,
2010). Ascorbate released from the astrocytes may reduce ferric
iron to ferrous iron locally in the brain extracellular fluid, which
can enable uptake and transport of NTBI by DMT1. Possibly
discouraging this hypothesis, DMT1 in transfected astrocytes is
not expressed in the cellular membrane but inside the cytosol
(Pelizzoni et al., 2012). A second route may mediate uptake of
ferric iron by a mechanism independent of transferrin receptors
or ascorbate/DMT1 (Lane et al., 2010), and conditions with
limitations in ascorbate may switch iron uptake to this route.
Concurrent with this theory, DMT1 does not seem to co-localise
with transferrin receptors in vesicles of cultured astrocytes
(Pelizzoni et al., 2012). Inflammatory stimuli with TNF-α or
IL-6 increase the expression of DMT1 in neurons, astrocytes,
and microglia. They also induce the expression of hepcidin in
astrocytes andmicroglia, but not in neurons (Urrutia et al., 2013).
Future Perspectives for DMT1 Research
The importance of DMT1 for cellular iron uptake is evident,
but many questions regarding its regulation remain. Insight into
this highly complex regulation will increase the understanding
of cellular iron uptake among neurons and glia and shed light
on the treatment of diseases with altered iron metabolism. Vital
questions on the understanding of iron transport at the BBB not
only includes the role of DMT1, but also the roles of proteins
like Steap and ferroportin for iron transport. Future studies
should address these proteins and their roles for iron transport
in experimental models of the BBB.
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